Regulation - Jakavi

Filter

Current filters:

Jakavi

Popular Filters

$25 million milestone for Incyte on Japanese approval of Jakavi

$25 million milestone for Incyte on Japanese approval of Jakavi

08-07-2014

US biopharma company Incyte says it has earned a $25 million milestone payment from Swiss drug major…

BiotechnologyBusiness FinanceBusiness FinanceFinancialIncyteJakaviJapanMajorMedicineNovartisOncologyRegulationRuxolitinib

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

07-03-2014

Swiss pharma major Novartis today announced positive results from a pivotal Phase III trial of Jakavi…

IncyteJakaviNovartisOncologyPharmaceuticalRare diseasesRegulationResearch

Setback for myelofibrosis patients as UK's NICE rejects Novartis' Jakavi

26-06-2013

Swiss drug major Novartis today (June 26) expressed disappointment at the decision of UK drugs watch…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

UK's NICE says no to Novartis' Jakavi for enlarged spleen

26-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft…

EuropeJakaviNovartisPharmaceuticalPricingRegulation

UK's NICE says no to Novartis' Jakavi for myelofibrosis in draft guidance

13-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (February…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

29-08-2012

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

Back to top